JoVE Visualize What is visualize?
Stop Reading. Start Watching.
Advanced Search
Stop Reading. Start Watching.
Regular Search
Find video protocols related to scientific articles indexed in Pubmed.
Targeting systolic anterior motion and left ventricular outflow tract obstruction in hypertrophic obstructed cardiomyopathy with a MitraClip.
EuroIntervention
PUBLISHED: 08-30-2014
Show Abstract
Hide Abstract
Aims: Hypertrophic obstructive cardiomyopathy (HOCM) with left ventricular outflow tract obstruction frequently involves a systolic anterior motion (SAM) of the anterior mitral leaflet. We hypothesised that SAM could be a new target for MitraClip therapy. Methods and results: Three patients with HOCM were chosen for MitraClip therapy, due to significant SAM with subsequent mitral regurgitation. Invasive haemodynamic studies (right heart catheterisation, simultaneous transaortic pressure recording, and administration of nitroglycerine) were performed before and after MitraClip implantation, and a six-week follow-up was undertaken. MitraClip implantation was successfully performed with significant reduction of mitral regurgitation and SAM in all patients. Basal peak gradients (before clip: 65±25.5 mmHg; after clip: 7.7±5.0 mmHg) as well as provoked pressure gradients (before clip: 145.3±8.1 mmHg; after clip: 23.2±7.6 mmHg) were significantly reduced after MitraClip implantation. Right heart catheterisation data did not reveal major changes. At six-week follow-up, all patients presented in a persistently improved clinical state (NYHA Class I-II) with insignificant residual MR and continuously reduced LVOT gradients. Conclusions: This is the first catheter-based study targeting primarily a SAM in HOCM to reduce LVOT obstruction. The results prove the concept that SAM is more than an epiphenomenon in HOCM. Thus, SAM-induced obstruction might be a valuable target for the MitraClip.
Related JoVE Video
Initial german experience with transapical implantation of a second-generation transcatheter heart valve for the treatment of aortic regurgitation.
JACC Cardiovasc Interv
PUBLISHED: 08-13-2014
Show Abstract
Hide Abstract
This analysis reports on the initial German multicenter experience with the JenaValve (JenaValve Technology GmbH, Munich, Germany) transcatheter heart valve for the treatment of pure aortic regurgitation.
Related JoVE Video
Impact of transcatheter aortic valve implantation (TAVI) on pulmonary hyper-tension and clinical outcome in patients with severe aortic valvular stenosis.
Clin Res Cardiol
PUBLISHED: 07-20-2014
Show Abstract
Hide Abstract
Transcatheter aortic valve implantation (TAVI) is a proven alternative to open heart surgery in elderly patients. Pulmonary hypertension (PH) is known as a significant risk factor in patients with severe aortic stenosis (AS) undergoing surgical aortic valve replacement. However, the prognostic impact of PH in high-risk patients undergoing TAVI is still unknown. The aim of this study was to gain more insight in the clinical outcome and mortality of patients with PH after TAVI.
Related JoVE Video
Balloon-expandable valves for degenerated mitral xenografts or failing surgical rings.
EuroIntervention
PUBLISHED: 06-22-2014
Show Abstract
Hide Abstract
Transcatheter mitral valve-in-valve implantation (TMViVI) for the treatment of failing mitral xenografts or recurrent mitral regurgitation after surgical ring implantation is an emerging therapy for patients in need of repeated mitral valve surgery. Despite the fact that these procedures have been shown to be feasible and effective, haemodynamic data after TMViVI are still limited in the literature.
Related JoVE Video
Predictors of 1-year mortality in patients with aortic regurgitation after transcatheter aortic valve implantation: an analysis from the multicentre German TAVI registry.
Heart
PUBLISHED: 06-03-2014
Show Abstract
Hide Abstract
Residual aortic regurgitation (AR) after transcatheter aortic valve implantation (TAVI) has been associated with increased mortality. Nevertheless, a considerable proportion of these patients survives and appears to tolerate AR. Identification of patients at higher risk of death may assist in tailoring therapy, but predictors of mortality in this subset of patients is largely unknown.
Related JoVE Video
Transcatheter aortic valve implantation of a second-generation valve for pure aortic regurgitation: procedural outcome, haemodynamic data and follow-up.
Interact Cardiovasc Thorac Surg
PUBLISHED: 06-03-2014
Show Abstract
Hide Abstract
The second-generation Jenavalve prosthesis (Jenavalve Technology, Inc., Munich, Germany) is the first transcatheter valve Conformité Européene (CE) marked for treatment of both aortic stenosis (AS) and pure aortic regurgitation (AR). Although the feasibility of the Jenavalve transcatheter aortic valve implantation (TAVI) in patients with pure AR has been described, haemodynamic and follow-up data are lacking.
Related JoVE Video
New evidence for favourable effects on haemodynamics and ventricular performance after Parachute(®) implantation in humans.
Eur. J. Heart Fail.
PUBLISHED: 05-13-2014
Show Abstract
Hide Abstract
The Parachute(®) Ventricular Partitioning Device offers an additional strategy for heart failure patients with exclusion of the infarcted wall to decrease left ventricular volumes, myocardial work, and wall stress. The aim of the present study was to evaluate if Parachute implantation might influence acute haemodynamic and functional performance in patients with left ventricular aneurysm after anteroapical infarction.
Related JoVE Video
Blood transfusion is associated with impaired outcome after transcatheter aortic valve implantation.
Catheter Cardiovasc Interv
PUBLISHED: 04-20-2014
Show Abstract
Hide Abstract
We sought to evaluate the relationship of blood transfusion after transcatheter aortic valve implantation (TAVI) and mid-term outcome to improve patient selection and periprocedural treatment.
Related JoVE Video
Comparison of balloon-expandable vs self-expandable valves in patients undergoing transcatheter aortic valve replacement: the CHOICE randomized clinical trial.
JAMA
PUBLISHED: 04-01-2014
Show Abstract
Hide Abstract
Transcatheter aortic valve replacement (TAVR) is an effective treatment option for high-risk patients with severe aortic stenosis. Different from surgery, transcatheter deployment of valves requires either a balloon-expandable or self-expandable system. A randomized comparison of these 2 systems has not been performed.
Related JoVE Video
Treatment of aortic stenosis with a self-expanding transcatheter valve: the International Multi-centre ADVANCE Study.
Eur. Heart J.
PUBLISHED: 03-28-2014
Show Abstract
Hide Abstract
Transcatheter aortic valve implantation has become an alternative to surgery in higher risk patients with symptomatic aortic stenosis. The aim of the ADVANCE study was to evaluate outcomes following implantation of a self-expanding transcatheter aortic valve system in a fully monitored, multi-centre 'real-world' patient population in highly experienced centres.
Related JoVE Video
MitraClip implantation as a new treatment strategy against systolic anterior motion-induced outflow tract obstruction in hypertrophic obstructive cardiomyopathy.
Heart Lung Circ
PUBLISHED: 01-07-2014
Show Abstract
Hide Abstract
We report on catheter-based treatment of left ventricular outflow tract (LVOT) obstruction targeting primarily a systolic anterior motion of the anterior mitral leaflet in hypertrophic obstructive cardiomyopathy (HOCM). A patient was successfully treated with the MitraClip two years after septal myectomy in conjunction with mitral valve repair. The results prove the concept, that systolic anterior motion (SAM) is clearly involved in gradient formation and is more than an epiphenomenon in HOCM. Thus, SAM-induced subaortic obstruction might be a target for MitraClip implantation.
Related JoVE Video
Clinical impact of paravalvular leaks on biomarkers and survival after transcatheter aortic valve implantation.
Catheter Cardiovasc Interv
PUBLISHED: 11-22-2013
Show Abstract
Hide Abstract
There is accumulating evidence that up to 20% of the implanted devices after TAVI are associated with a significant degree of paravalvular leaks, which appear to be associated with a negative clinical outcome.
Related JoVE Video
Radiotherapy in langerhans cell histiocytosis - a rare indication in a rare disease.
Radiat Oncol
PUBLISHED: 06-04-2013
Show Abstract
Hide Abstract
Langerhans Cell Histiocytosis (LCH) represents a rare benign disorder, previously designated as "Histiocytosis X", "Type II Histiocytosis" or "Langerhans Cell Granulomatosis". Clinical presentation includes osteolysis, ulcerations of skin and soft tissues but also involvement of the CNS is described.Because treatment concepts are not well defined the German Cooperative Group on Radiotherapy for Benign Diseases performed a retrospective analysis.
Related JoVE Video
Aortic aneurysm 18 month after transfemoral implantation of a self-expandable aortic valve prosthesis.
Catheter Cardiovasc Interv
PUBLISHED: 05-04-2013
Show Abstract
Hide Abstract
We report a case of a new developed aortic aneurysm 18 month after transcatheter aortic valve implantation in an 80-year-old woman. The abnormality was an incidental finding during routine coronary angiography.
Related JoVE Video
MitraClip® via direct right atrial access in case of a missing inferior vena cava.
EuroIntervention
PUBLISHED: 03-14-2013
Show Abstract
Hide Abstract
The presence of mitral regurgitation (MR) in patients with heart failure represents an independent predictor of mortality. Until now, the standard therapy for severe MR has been cardiac surgery in order to perform mitral valve replacement or mitral valve repair. With the introduction of the MitraClip® system (Abbott Vascular - Structural Heart, Menlo Park, CA, USA) in 2008, there is now an alternative percutaneous treatment option available for high-risk patients. We report on an 84-year-old male patient who was admitted to the emergency room with increasing shortness of breath due to severe functional MR, at stage NYHA III. In the following days the patient developed cardiogenic shock due to failure of the diuretic medication. The case first described here demonstrates an alternative transseptal route of access via a direct atrial puncture of the RA in a patient with absent inferior vena cava. This approach was successfully used to perform a MitraClip® procedure in this patient with functional MR and cardiogenic shock. It was possible to treat mitral regurgitation and the consecutive cardiogenic shock by implanting two MitraClips®.
Related JoVE Video
Percutaneous mitral valve interventions in the real world: early and 1-year results from the ACCESS-EU, a prospective, multicenter, nonrandomized post-approval study of the MitraClip therapy in Europe.
J. Am. Coll. Cardiol.
PUBLISHED: 02-07-2013
Show Abstract
Hide Abstract
The purpose of this article is to report early and mid-term outcomes of the ACCESS-EU study (ACCESS-Europe A Two-Phase Observational Study of the MitraClip System in Europe), a European prospective, multicenter, nonrandomized post-approval study of MitraClip therapy (Abbott Vascular, Inc., Santa Clara, California).
Related JoVE Video
Transcatheter aortic valve replacement with a new self-expanding transcatheter heart valve and motorized delivery system.
JACC Cardiovasc Interv
PUBLISHED: 01-04-2013
Show Abstract
Hide Abstract
The aim of this study was to demonstrate feasibility and short- and midterm clinical outcomes with a new self-expanding transcatheter heart valve and motorized delivery system.
Related JoVE Video
Valve-in-valve transcatheter aortic valve implantation for degenerated bioprosthetic heart valves.
JACC Cardiovasc Interv
PUBLISHED: 07-07-2011
Show Abstract
Hide Abstract
We sought to analyze outcomes of patients with degenerated surgically implanted bioprosthetic heart valves undergoing valve-in-valve (viv) transcatheter aortic valve implantation (TAVI).
Related JoVE Video
Radiotherapy of splenomegaly : a palliative treatment option for a benign phenomenon in malignant diseases.
Strahlenther Onkol
PUBLISHED: 01-24-2011
Show Abstract
Hide Abstract
Since the 20(th) century, radiotherapy (RT) has been used for treatment of symptomatic splenomegaly (SM). SM occurs in association with hematologic disorders. The purpose of this analysis was to determine the indication, treatment concepts, and efficiency of RT.
Related JoVE Video
Selective follicular targeting by modification of the particle sizes.
J Control Release
PUBLISHED: 08-26-2010
Show Abstract
Hide Abstract
Hair follicles represent interesting target sites for topically applied substances such as topical vaccinations or agents used in the field of regenerative medicine. In recent years, it could be shown that particles penetrate very effectively into the hair follicles. In the present study, the influence of particle size on the follicular penetration depths was examined. The penetration depths of two different types of particles sized 122 to 1000 nm were determined in vitro on porcine skin. The results revealed that the particles of medium size (643 and 646 nm, respectively) penetrated deeper into the porcine hair follicles than smaller or larger particles. It was concluded that by varying the particle size, different sites within the porcine hair follicle can be targeted selectively. For the human terminal hair follicle, the situation can be expected to be similar due to a similar size ratio of the hair follicles.
Related JoVE Video
Selenium substitution during radiotherapy of solid tumours - laboratory data from two observation studies in gynaecological and head and neck cancer patients.
Anticancer Res.
PUBLISHED: 07-02-2010
Show Abstract
Hide Abstract
Selenium is an essential cofactor of the enzyme glutathione peroxidase (GSH-Px), which is important for the endogenous detoxification of free radicals. A reduced activity of GSH-Px is related to increased toxicities due to radiation therapy during primary cancer treatment. Therefore, selenium substitution may be a new supportive strategy to diminish radiation-associated side effects.
Related JoVE Video
Variation of in vitro human skin permeation of rose oil between different application sites.
Forsch Komplementmed
PUBLISHED: 06-14-2010
Show Abstract
Hide Abstract
Rose oil is the essential oil extracted from the petals of the damask rose. It is an ingredient of cosmetic as well as health care products and it is used in folk medicine and in aromatherapy. It is well known that essential oils are able to permeate the skin whereas the lipophilic properties of the compounds as well as the application site have an influence on their permeation behaviour. In this paper, we investigated the influence of the application site on the permeation of rose oil.
Related JoVE Video
Percutaneous aortic valve replacement: overview and suggestions for anesthestic management.
J Clin Anesth
PUBLISHED: 04-22-2010
Show Abstract
Hide Abstract
Transcutaneous aortic valve replacement (AVR) is increasingly used for high-risk patients with severe aortic stenosis, who have high operative mortality for surgical placement during cardiopulmonary bypass (CPB). Retrograde transfemoral AVR is usually performed during sedation, whereas antegrade transapical AVR is done with general anesthesia. Both procedures can be carried out without CPB. Extended hemodynamic monitoring, including pulmonary artery catheterization and transesophageal echocardiography, may be useful. Transfemoral AVR requires placement of a transvenous right ventricular pacing lead. Typical complications include local bleeding, obstruction of the coronary ostia, and neurological insult due to embolization of sclerotic material. Aortic regurgitation due to paravalvular leakage or inadequate device expansion also may occur. Renal function may deteriorate on excessive application of contrast medium. Atrioventricular blocks may occur later rather than after conventional AVR which tend to occur immediately.
Related JoVE Video
U73122, an aminosteroid phospholipase C inhibitor, is a potent inhibitor of cardiac phospholipase D by a PIP2-dependent mechanism.
J. Cardiovasc. Pharmacol.
PUBLISHED: 02-25-2010
Show Abstract
Hide Abstract
The aminosteroid 1-[6-({17beta-3-methoxyestra-1,3,5(10)-trien-17-yl}amino)hexyl]-1H-pyrrole-2,5-dione (U73122) has been extensively used as a pharmacologic inhibitor of phospholipase C (PLC). The inhibitory effect of U73122 on PLC activity is most likely the result of decreased availability of phosphatidylinositol 4,5-bisphosphate (PIP2), the substrate of the PLC signal transduction pathway, rather than direct inhibition of the enzyme. PIP2 is a phospholipid with pleiotropic cellular functions, including a pivotal role in regulating cardiac phospholipase D (PLD) signal transduction. Here, we hypothesized that U73122 acts as an inhibitor of cardiac PLD activity by interference with PIP2. U73122 concentration-dependently inhibited PLD activity in rat myocardial membranes. The inhibitory effect of U73122 was significantly attenuated when assayed on solubilized PLD activity and was completely restored if solubilized PLD activity was assayed in the presence of PIP2. U73122 had no inhibitory effect on purified PLD indicating that the substance does not interact with PLD directly. These data highlight a mechanism of action of U73122 as an inhibitor of myocardial PLD by interaction with PIP2 as a cofactor for optimal PLD activity. Hence, studies using U73122 as a specific inhibitor of PLC have to take into account that PLD may be involved in some of the effects ascribed to PLC.
Related JoVE Video
[Percutaneous approaches for mitral valve interventions--a real alternative technique for standard cardiac surgery?].
Herz
PUBLISHED: 09-29-2009
Show Abstract
Hide Abstract
Standard therapy of advanced mitral valve regurgitation currently consists of mitral valve reconstruction through heart surgery including heart-lung machine employment. Typically, a ring is implanted and a leaflet reduced, if necessary, to approximate the posterior and anterior mitral valve leaflets to each other. Because of high comorbidity among this patient population, new and less burdening catheter-based techniques have been developed. Clinical etiology of mitral valve regurgitation is divided into two categories: "structural" versus "functional". The MONARC system of the Edwards Lifesciences company consists of three components--distal stent, bridge with bioabsorbing coating, proximal stent--and is implanted into the coronary sinus. The underlying principle is an indirect annuloplasty of the mitral valve annulus resulting from resorption of the bridge coating and leading to a reduction and indirect tightening of the mitral valve annulus. The EVOLUTION I (EV I) study in patients suffering from functional mitral regurgitation to a degree between 2+ and 4+ revealed--12 months after the MONARC implantation--a mitral valve regurgitation reduction from 2.48 to 1.78. The EV I study found interaction of the foreshortening bridge with the coronary arteries in some patients. This problem is most widely excluded by previous computed tomographic or angiographic examinations in the ongoing follow-up study EV II. Direct annuloplasty is made possible in case of functional mitral regurgitation by using the Mitralign Percutaneous Annuloplasty System (MPAS) of the Mitralign company. In doing so, an improved coadaptation of the mitral valve leaflet is achieved by inserting three sutures into the posterior mitral valve annulus and subsequent plicating.The MitraClip of the Evalve company uses the principle of the edge-to-edge technique. In doing so, the posterior and anterior leaflets are joined by implanting a clip, resulting in a reduction of mitral regurgitation with two diastolic orifices. In contrast to strukthe other two procedures, the MitraClip can be used for both functional and structural mitral valve regurgitation. The EVEREST I study and the EVEREST II study, as far as it has already been published, show that this procedure is secure and its results are very positive. The previous results of all three procedures show that catheter-based techniques for treating high-risk patients suffering from mitral valve regurgitation arrive at positive results in part, so that possibly a real alternative to conventional heart surgery will be available in the future.
Related JoVE Video
Wistar rat skin as surrogate for human skin in nortriptyline hydrochloride patch studies.
Int J Pharm
PUBLISHED: 06-03-2009
Show Abstract
Hide Abstract
Six different matrices were prepared containing nortriptyline hydrochloride (NTH) with hydroxypropyl-methyl-cellulose as polymer. A mixture of transdermal enhancers was included as part of the vehicle. Diffusion studies were carried out through Wistar rat full thickness skin using Franz cells. They were compared with previously determined human heat separated epidermis in order to test if this animal can be used as model for in vivo assays. A linear correlation was obtained between NTH diffusion coefficients through both skin types (r2=0.996).
Related JoVE Video
Long-term results of radiotherapy in primary carcinoma of the vagina.
Strahlenther Onkol
PUBLISHED: 03-28-2009
Show Abstract
Hide Abstract
The long-term results of radiotherapy in primary carcinoma of the vagina are not well defined.
Related JoVE Video
A Drosophila pasha mutant distinguishes the canonical microRNA and mirtron pathways.
Mol. Cell. Biol.
PUBLISHED: 02-05-2009
Show Abstract
Hide Abstract
Canonical primary microRNA (miRNA) transcripts and mirtrons are proposed to transit distinct nuclear pathways en route to generating mature approximately 22 nucleotide regulatory RNAs. We generated a null allele of Drosophila pasha, which encodes a double-stranded RNA-binding protein partner of the RNase III enzyme Drosha. Analysis of this mutant yielded stringent evidence that Pasha is essential for the biogenesis of canonical miRNAs but is dispensable for the processing and function of mirtron-derived regulatory RNAs. The pasha mutant also provided a unique tool to study the developmental requirements for Drosophila miRNAs. While pasha adult somatic clones are similar in many respects to those of dicer-1 clones, pasha mutant larvae revealed an unexpected requirement for the miRNA pathway in imaginal disc growth. These data suggest limitations to somatic clonal analysis of miRNA pathway components.
Related JoVE Video
[Radiotherapy in painful gonarthrosis. Results of a national patterns-of-care study].
Strahlenther Onkol
PUBLISHED: 01-29-2009
Show Abstract
Hide Abstract
After a patterns-of-care study (PCS) in 2003/2004 addressing benign disorders in general, the German Cooperative Group on Radiotherapy for Benign Diseases (GCG-BD) conducted several multicenter cohort studies including the use of radiotherapy (RT) in painful gonarthrosis (GNA).
Related JoVE Video
The significance of postprocedural aortic regurgitation after transcatheter aortic valve implantation on postprocedural prognosis.
Future Cardiol
Show Abstract
Hide Abstract
Transcatheter aortic valve implantation (TAVI) is becoming a more and more important treatment for aortic valve stenosis in high-risk surgical patients. Furthermore, there currently is a discussion for the expansion of TAVI to intermediate-risk patients. In the past, surgical aortic valve replacement was the standard treatment, with excellent results in hemodynamic, as well as echocardiographic parameters and survival rates. However, the results of the Partner A and Partner B trials, as well as the ADVANCE study demonstrate the promise of establishing TAVI as a real alternative treatment option for aortic valve stenosis. One of the risks of a TAVI procedure is the occurrence of aortic regurgitation (AR) post-TAVI. Mild AR is a common finding after TAVI and seems not to be a clinical problem; however, occurrence of significant postprocedural AR after TAVI is still a problem. There is a clear association between significant postprocedural AR and clinical outcomes. Therefore, this review focuses on the occurrence, reasons, diagnostics, clinical impact and treatment options of AR post-TAVI.
Related JoVE Video
Ipsilateral arterial access for management of vascular complication in transcatheter aortic valve implantation.
Catheter Cardiovasc Interv
Show Abstract
Hide Abstract
Transcatheter aortic valve implantation (TAVI) requires appropriate vascular access. Access site complications remain an important clinical issue. We report a new access site technique for management of puncture site visualization, reduction in use of contrast dye, in addition to several treatment options for management of vascular complications.
Related JoVE Video
Direct percutaneous access technique for transaxillary transcatheter aortic valve implantation: "the Hamburg Sankt Georg approach".
JACC Cardiovasc Interv
Show Abstract
Hide Abstract
This study questioned whether transaxillary transcatheter aortic valve implantation (TAVI) is feasible as a true percutaneous approach using percutaneous closure devices.
Related JoVE Video

What is Visualize?

JoVE Visualize is a tool created to match the last 5 years of PubMed publications to methods in JoVE's video library.

How does it work?

We use abstracts found on PubMed and match them to JoVE videos to create a list of 10 to 30 related methods videos.

Video X seems to be unrelated to Abstract Y...

In developing our video relationships, we compare around 5 million PubMed articles to our library of over 4,500 methods videos. In some cases the language used in the PubMed abstracts makes matching that content to a JoVE video difficult. In other cases, there happens not to be any content in our video library that is relevant to the topic of a given abstract. In these cases, our algorithms are trying their best to display videos with relevant content, which can sometimes result in matched videos with only a slight relation.